The logic behind popular brands and new consumer trends for Generation Z is dissected, with data revealing who is capturing the value. In the cosmetics industry supply chain, functional ingredients are often described as the critical 'chip' that determines a product's success or failure. Shanghai JiaKai Biotechnology Co., Ltd. (JiaKai Biotech) is a company striving to lead in this specialized segment. Adorned with titles like 'Specialized and Sophisticated SME' and 'High-Tech Enterprise', and boasting an impressive client list including Proya Cosmetics Co., Ltd., Bloomage Biotechnology Corporation Limited, and GIANT BIOGENE, the company has successfully passed the listing review by the Beijing Stock Exchange, with only the final registration and issuance step remaining before its market debut.
However, beneath the grand narrative in its prospectus about being 'deeply integrated into the core ecosystem of China's cosmetics industry,' the path to this initial public offering for the self-proclaimed top-five industry player is riddled with obstacles. From puzzling capital increases and decreases executed within a single day, to a receivables turnover ratio significantly below the industry average; from a paradox of pursuing massive fund-raising for capacity expansion despite low existing utilization rates, to a 'top-five' market positioning backed by a mere 1.64% market share—regulators have issued multiple rounds of inquiries targeting its compliance and business logic vulnerabilities.
For JiaKai Biotech, this capital market test examines not only the quality of its financial data but also the coherence of its underlying business model.
Contrasting Financial Performance: Strengths and Weaknesses
On the surface, JiaKai Biotech presents a picture of steady financial growth. In 2024, the company achieved operating revenue of 242 million yuan and a net profit attributable to shareholders of 56.94 million yuan. For the first three quarters of 2025, revenue reached 195 million yuan with a net profit of 47.30 million yuan. More notably, its profitability has been robust, with the company's comprehensive gross profit margin consistently remaining above 63% from 2023 to 2025. In 2024, the gross margin for its core 'Green Natural Ingredient Products' was as high as 78.18%.
Yet, this high gross margin stands in stark contrast to another critical financial metric. In 2025, the company's accounts receivable turnover was only 5.47 times, while the industry average for the same period was 18.46 times. This indicates that JiaKai Biotech's cash collection cycle is far longer than its peers. Amid intensifying competition in the cosmetic ingredients sector, there is reasonable market skepticism: is this exceptionally high gross margin being achieved by extending customer payment terms and relaxing credit policies? When profit growth is built on sacrificing cash flow, the risk of bad debts from prolonged collection periods quietly undermines the quality of the reported profits.
Further analysis of its growth trajectory reveals additional concerns. While the compound annual growth rate for operating revenue over the past three years was 15.22%, the corresponding figure for net profit was only 2.21%. A more contradictory aspect lies in its expense structure. As a high-tech enterprise ostensibly driven by technology and R&D, JiaKai Biotech's R&D expenses in 2025 were 19.36 million yuan, accounting for just 7.37% of its revenue—a figure below the average of comparable companies. In the same period, its sales expenses were significantly higher at 42.34 million yuan, more than double the R&D spend.
Governance Concerns and Regulatory Scrutiny
If financial data issues can be partially attributed to industry cycles, the capital maneuvers in its equity history directly touch upon compliance red lines for IPO reviews.
The company's equity history is marked by perplexing transactions. In May 2020, its registered capital surged from 10 million yuan to 50 million yuan. Merely five months later, in October of the same year, a capital reduction process was initiated, reducing it back by 40 million yuan. This unusual pattern of a 'large, short-term capital increase followed by a rapid, full reduction' prompted stern inquiries from the Beijing Stock Exchange regarding potential personal income tax evasion, undisclosed shareholding arrangements, or improper benefit transfers. The company's responses have so far failed to provide complete fund flow records and tax payment certificates to fully address these concerns.
Confusion also surrounds the pricing of its share transfers. In August 2022, within the same period, share transfers occurred at three different price points: 59.01 yuan, 88.76 yuan, and 98.62 yuan, a spread of nearly 40 yuan. More curiously, less than a year and a half later in January 2024, the price for a new round of capital increase was halved to 48.5 yuan, even lower than the previous lowest tier.
At the corporate governance level, the prospectus emphasizes a 'joint control' structure by three individuals: Tian Jun, Wang Jichao, and Su Wencai. In practice, however, this appears more like the absolute dominance of Tian Jun, who controls 41.85% of the voting rights, while the other two collectively control 32.29%. With rules stating that 'in case of disagreement, the outcome is determined by the party with the higher proportion of voting rights,' the concept of joint control seems nominal. More alarmingly, this concerted action agreement is only valid until June 2028. Should core management diverge in interests or engage in post-listing share sales, the risk of a change in control could significantly impact the company's operational stability.
Strategic Contradictions and Market Position
The IPO aims to raise approximately 310 million yuan, with a core purpose of building a '50-ton Annual Functional Plant Extract Project.' However, this seemingly focused strategic plan appears logically disconnected from the company's current operational reality.
The prospectus reveals that the company's existing production capacity is not fully utilized. From 2023 to 2025, the capacity utilization rates for its green natural ingredient products were 61.19%, 49.87%, and 68.34%, respectively. For its bio-fermentation products, the rates were even lower at 19.32%, 25.33%, and 22.45%. This indicates significant idle capacity in its current production lines.
Although the company explains that the fundraising project is for high-end product upgrades, and industry experts note that capacity utilization is generally lower in emerging fields like synthetic biology, the logic of 'expanding production massively while existing capacity sits idle' still exposes aggressive and potentially risky strategic decision-making.
Examining the competitive landscape, there is a substantial gap between JiaKai Biotech's self-positioning and its actual market standing. The company claims to be 'among the top five in the Chinese cosmetics functional ingredients market.' Yet, according to relevant data, its domestic market share in functional ingredients in 2024 was only about 1.64%. The Beijing Stock Exchange has explicitly requested the company to justify this claim in its second round of inquiries.
Meanwhile, JiaKai Biotech has built a product system encompassing 'plant extraction, bio-fermentation, and chemical synthesis' but has not yet ventured into the currently hot field of synthetic biology. In contrast, peers like Bloomage Biotechnology Corporation Limited and GIANT BIOGENE have long been deeply engaged in synthetic biology, reshaping the industry landscape through technological advancements. With relatively conservative R&D investment and technology roadmap choices, whether JiaKai Biotech can maintain its current competitive edge amidst pressure from giants and rapid technological iteration remains a significant question.
The capital market is never short of compelling stories, but it often lacks rigorously scrutinized truths. JiaKai Biotech demonstrates a certain business foundation, leveraging the promising cosmetics functional ingredients sector and endorsements from leading clients. However, for a company on the verge of a public listing, only by genuinely streamlining internal governance, solidifying technological barriers, and aligning its financial data with sound business logic can it present a performance that truly withstands the test of time under the spotlight of public capital markets.
Comments